Robert A Ashley

This inventor holds 17 USPTO granted patents and 5 published patent applications, plus 2 CIPO patents, primarily in Acne Treatment. Top assignees: Collagenex Pharmaceuticals, Incorporated, Galderma Laboratories Inc., Other. Active years: 1998-2018.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Robert A Ashley. Retrieved from https://idiyas.com/inventor/robert-a-ashley

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 17 (Patent Applications = 5)

% Patents Active = 47.1

CIPO Patents = 2 (Patent Applications = 2)

Average Co-Inventor Count = 1.2

ph-index = 11

Forward Citations = 310(Granted Patents)

Location History:

Newton, PA (US) (2003)
Tucson, AZ (US) (2007)
Encinitas, CA (US) (2014)
Newtown, PA (US) (1998 - 2018)

Company Filing History:

9 out of 10

Collagenex Pharmaceuticals, Incorporated

patents

7 out of 27

Galderma Laboratories Inc.

patents

1 out of 834,570

Other

patents

Years Active: 1998-2018

Loading Chart...

Areas of Expertise:

Acne Treatment

Rosacea Treatment

4-Dedimethylaminotetracycline

Ocular Rosacea

Telangiectasia

Dentin Hypersensitivity

H. Pylori

Drug Delivery

17 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10058564 - Methods of treating acne (2018-08-28),

2. 9241946 - Methods of treating acne (2016-01-26),

3. 8658189 - Methods of treating acne (2014-02-25),

4. 8603506 - Methods of treating acne (2013-12-10),

5. 8192749 - Methods of simultaneously treating ocular rosacea and acne rosacea (2012-06-05),

6. 8052983 - Methods of treating acne (2011-11-08),

7. 7456158 - 4-dedimethylaminotetracycline derivatives (2008-11-25),

8. 7232572 - Methods of treating rosacea (2007-06-19),

9. 7211267 - Methods of treating acne (2007-05-01),

10. 7014858 - Use methods of treating acne and telangiectasia (2006-03-21),

11. 7008631 - Methods of simultaneously treating ocular rosacea and acne rosacea (2006-03-07),

12. 6946453 - 4-dedimethylaminotracycline derivatives (2005-09-20),

13. 6894036 - 4-dedimethylaminotetracycline derivatives (2005-05-17),

14. 6638922 - 4-dedimethylaminotetracycline derivatives (2003-10-28),

15. 6506740 - 4-dedimethylaminotetracycline derivatives (2003-01-14),

Title: The Innovative Contributions of Robert A. Ashley

Introduction

Robert A. Ashley is a notable inventor based in Newtown, Pennsylvania, recognized for his significant contributions to the field of dermatology. With a total of 17 patents to his name, Ashley has focused primarily on methods for treating acne, showcasing his dedication to improving skin health.

Latest Patents

Among his latest patents, Ashley has developed innovative methods for treating acne. One of his notable inventions involves administering a tetracycline compound systemically to individuals in need, ensuring effective acne treatment without the antibiotic activity typically associated with such compounds. This method also avoids the use of bisphosphonate compounds, highlighting his focus on safety and efficacy in treatment.

Career Highlights

Throughout his career, Robert A. Ashley has worked with prominent companies in the pharmaceutical industry, including Collagenex Pharmaceuticals, Incorporated and Galderma Laboratories Inc. His work in these organizations has allowed him to contribute to the development of effective acne treatments, further establishing his reputation as a leading inventor in this field.

Collaborations

Ashley has collaborated with several professionals in his field, including Joseph J. Hlavka and Joseph J. Hlavaka. These collaborations have likely enriched his research and development efforts, leading to innovative solutions in acne treatment.

Conclusion

Robert A. Ashley's contributions to dermatology through his inventive methods for treating acne demonstrate his commitment to advancing medical science. His work continues to impact the lives of many individuals seeking effective skin care solutions.

Profile summary based on public USPTO records.